Factors associated with neoadjuvant therapy insensitivity and its prognostic impact in HER2-positive breast cancer [0.03%]
HER2阳性乳腺癌新辅助治疗非敏感因素及其预后影响分析
Yuhang Han,Bo Lan,Zexi Peng et al.
Yuhang Han et al.
Objective: A subset of patients with human epidermal growth factor receptor 2 positive (HER2+) breast cancer shows insensitivity to neoadjuvant therapy (NAT), often evidenced by imaging results indicating stable disease (...
Diagnostic sensitivity of mammography and magnetic resonance imaging for ductal carcinoma in situ in high-risk breast cancer screening: A systematic-review and meta-analysis [0.03%]
高风险乳腺癌筛查中乳管内原位癌的乳腺X线摄影和磁共振成像诊断敏感性：系统评价和Meta分析
Mengmeng Li,Yixuan Lin,Keris Poelhekken et al.
Mengmeng Li et al.
Objective: Given the improved sensitivity of magnetic resonance imaging (MRI) for detecting ductal carcinoma in situ (DCIS), the omission of routine mammography (MG) or digital breast tomosynthesis (DBT) in high-risk brea...
Development and validation of a clinical risk-prediction model for immune checkpoint inhibitor-related pneumonitis in patients with gastrointestinal cancer based on four machine learning algorithms [0.03%]
基于四种机器学习算法的免疫检查点抑制剂相关肺炎临床预测模型的建立和验证（胃肠道肿瘤患者）
Yixuan Wang,Liyan Zhang,Zhenzhen Su et al.
Yixuan Wang et al.
Objective: Immune checkpoint inhibitor-related pneumonitis (ICIP) is a common and potentially life-threatening adverse event with non-specific symptoms. It is of significance to identify high-risk population of ICIP. Howe...
Evolving diagnostic and surveillance strategies in esophageal cancer screening: Evidence from population-based studies in China [0.03%]
基于中国人群的研究推动食管癌筛查诊断和监测策略的改进
Zhonghu He,Yang Ke
Zhonghu He
Esophageal cancer (EC) is one of the most common malignancies in China, accounting for over half of the world's new cases and deaths, and posing a severe threat to national health. Currently, the prevention and control of EC primarily rely ...
Cancer statistics in China: Epidemiology, risk factors, and prevention [0.03%]
中国癌症的流行病学、危险因素及预防措施统计分析报告
Wei Cao,Kang Qin,Bingyang Liu et al.
Wei Cao et al.
Cancer is a leading cause of death in China, and its epidemiological profile has shifted markedly in recent years. This review summarizes contemporary trends in cancer incidence and mortality, delineates the major modifiable risk factors, a...
Epidemiology, early detection, and management of breast cancer in China: A comprehensive review [0.03%]
中国乳腺癌流行病学、早期发现和治疗的全面综述
Hangcheng Xu,Binghe Xu
Hangcheng Xu
Breast cancer represents a significant and growing public health challenge in China, marked by a rising incidence and distinct variations across age groups and geographical regions. This review synthesizes recent evidence regarding the epid...
Hematology specialist nurse-led continuity-of-care for high-risk hematopoietic cell transplantation recipients [0.03%]
血液科专科护士对高危造血干细胞移植受者的连续性护理
Ting Wang,Li Wu,Aiyun Jin et al.
Ting Wang et al.
A multicenter study of a predictive model for pathological complete response after neoadjuvant therapy in breast cancer using multimodal digital biomarkers [0.03%]
一项多中心研究：使用多种数字生物标志物预测新辅助治疗后乳腺癌病理完全缓解的模型
Zixuan Yang,Jie He,Taolang Li et al.
Zixuan Yang et al.
Objective: Neoadjuvant therapy (NAT) has become the standard treatment option for patients with locally advanced breast cancer. How to non-invasively screen out patients with pathological complete response (pCR) after NAT...
Leukemia epidemiology in China: Burden, trends, and determinants in the 21st century [0.03%]
中国白血病流行病学：21世纪的疾病负担、趋势与决定因素
Lijuan Hu,Yi Xia,Xiaojun Huang
Lijuan Hu
This comprehensive review integrates population-based registries, hospital databases and Global Burden of Disease data to describe the evolving leukemia burden in China from 2000 to 2022. The overall incidence has stabilized nationally, but...
Curcumol overcomes cisplatin resistance and rewires glycolysis-H3K9la-ORC6 axis to trigger ferroptosis in bladder cancer [0.03%]
姜黄素衍生物curcumol通过重新编程糖酵解-H3K9me-ORC6轴触发铁死亡从而克服膀胱癌细胞顺铂耐药性
Facai Zhang,Yunkai Yang,Rong Zhang et al.
Facai Zhang et al.
Objective: Cisplatin-based chemotherapy is a cornerstone for bladder cancer treatment, but the development of resistance remains a major clinical challenge. Curcumol, a bioactive sesquiterpenoid derived from Curcumae Rhiz...